- Vamorolone
-
- $31.00 / 1mg
-
2025-09-29
- CAS:13209-41-1
- Min. Order:
- Purity: 99.54%
- Supply Ability: 10g
|
| | Dexamethasone EP Impurity E Basic information |
| Product Name: | Dexamethasone EP Impurity E | | Synonyms: | 17,21-dihydroxy-16alpha-methylpregna-1,4,9(11)-triene-3,20-dione;16α-Methyl-9,11-dehydro Prednisolone;Dexamethasone impurity E;Dexamethasone Impurity 5(Dexamethasone EP Impurity E);(16α)-17,21-Dihydroxy-16-Methylpregna-1,4,9(11)-triene-3,20-dione;17.alpha.,21-Dihydroxy-16.alpha.-methylpregna-1,4,9(11)-triene-3,20-dione;Dexamethasone Impurity L;(8S,10S,13S,14S,16R,17R)-17-hydroxy | | CAS: | 13209-41-1 | | MF: | C22H28O4 | | MW: | 356.46 | | EINECS: | 236-177-8 | | Product Categories: | Intermediates & Fine Chemicals;Pharmaceuticals;Steroids | | Mol File: | 13209-41-1.mol |  |
| | Dexamethasone EP Impurity E Chemical Properties |
| Melting point | 228-231 °C(Solv: acetone (67-64-1); hexane (110-54-3)) | | Boiling point | 548.3±50.0 °C(Predicted) | | density | 1.24±0.1 g/cm3(Predicted) | | storage temp. | Refrigerator | | solubility | Chloroform (Slightly), Dioxane (Slightly), Ethyl Acetate (Slightly) | | form | Solid | | pka | 12.53±0.70(Predicted) | | color | Pale Yellow | | InChIKey | ZYTXTXAMMDTYDQ-JBFVNPOPNA-N | | SMILES | C1(=O)C=C2[C@](C)(C=C1)C1[C@]([H])([C@@]3([H])[C@@](CC=1)(C)[C@@](O)(C(=O)CO)[C@H](C)C3)CC2 |&1:4,9,11,13,17,23,r| |
| | Dexamethasone EP Impurity E Usage And Synthesis |
| Uses | A related intermediate of Prednisolone (P703740). | | Biological Activity | Vamorolone, a synthetic steroid, is an orally available dissociative steroid with anti-inflammatory efficacy. It is a partial agonist of the glucocorticoid receptor (NR3C1) th at appear to be safe and well tolerated. Also, vamorolone is a potent antagonist of the mineralocorticoid receptor (NR3C2). It is under development for children with Duchenne muscular dystrophy. | | in vivo | Vamorolone (5-30 mg/kg; cherry syrup) shows a superior side effect profile compared to pharmacological glucocorticoids in mdx mice[1].
?
Vamorolone (30 mg/kg; orally; daily for 20 days) reduces CNS Inflammation in murine experimental autoimmune encephalomyelitis[2]. | Animal Model: | C57BL/6 mice (experimental autoimmune encephalomyelitis)[2] | | Dosage: | 30 mg/kg | | Administration: | Orally; daily for 20 days (starting one day prior to MOG 33-55 peptide immunization and continuing) | | Result: | Reduced CNS inflammation in murine experimental autoimmune encephalomyelitis. |
| | Toxics Screening Level | The ITSL for 17, 21-dihydroxy-16 alpha-methylpregna-1,4,9 (11)-triene-3, 20-dione has been changed from 0.04 μg/m3 to 0.1 μg/m3 based on annual averaging time. |
| | Dexamethasone EP Impurity E Preparation Products And Raw materials |
|